iRhythm Technologies (IRTC) to Release Earnings on Thursday

iRhythm Technologies (NASDAQ:IRTC) is projected to issue its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $202.6060 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

iRhythm Technologies Price Performance

Shares of iRhythm Technologies stock opened at $144.21 on Tuesday. The company has a debt-to-equity ratio of 5.32, a current ratio of 4.63 and a quick ratio of 4.50. iRhythm Technologies has a one year low of $92.52 and a one year high of $212.00. The business’s 50 day simple moving average is $166.09 and its two-hundred day simple moving average is $171.72. The stock has a market capitalization of $4.65 billion, a P/E ratio of -89.57 and a beta of 1.06.

Analyst Upgrades and Downgrades

IRTC has been the topic of several analyst reports. Loop Capital set a $220.00 target price on shares of iRhythm Technologies in a research note on Friday, October 31st. The Goldman Sachs Group raised their price target on shares of iRhythm Technologies from $180.00 to $202.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. Evercore raised shares of iRhythm Technologies from an “in-line” rating to an “outperform” rating and upped their price objective for the company from $194.00 to $210.00 in a research note on Monday, January 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of iRhythm Technologies in a report on Thursday, January 22nd. Finally, Truist Financial reduced their price target on iRhythm Technologies from $230.00 to $215.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, iRhythm Technologies has a consensus rating of “Moderate Buy” and an average price target of $219.23.

Insider Transactions at iRhythm Technologies

In other iRhythm Technologies news, insider Patrick Michael Murphy sold 2,478 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $184.83, for a total value of $458,008.74. Following the completion of the sale, the insider directly owned 53,281 shares in the company, valued at $9,847,927.23. This trade represents a 4.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Chad Patterson sold 280 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $184.83, for a total value of $51,752.40. Following the transaction, the insider owned 43,387 shares in the company, valued at $8,019,219.21. This trade represents a 0.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.68% of the stock is owned by corporate insiders.

Institutional Trading of iRhythm Technologies

Hedge funds and other institutional investors have recently modified their holdings of the business. Measured Wealth Private Client Group LLC purchased a new position in iRhythm Technologies during the 3rd quarter valued at about $30,000. Employees Retirement System of Texas purchased a new stake in iRhythm Technologies in the third quarter worth about $36,000. Smartleaf Asset Management LLC increased its stake in shares of iRhythm Technologies by 63.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 323 shares of the company’s stock valued at $58,000 after purchasing an additional 125 shares in the last quarter. Harvest Fund Management Co. Ltd purchased a new position in shares of iRhythm Technologies during the third quarter valued at approximately $69,000. Finally, Kestra Advisory Services LLC bought a new stake in shares of iRhythm Technologies in the 4th quarter worth approximately $71,000.

About iRhythm Technologies

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.